EuBiologics（A206650）株式概要バイオ医薬品会社であるEuBiologics Co, Ltd.は、韓国で伝染病用のワクチンを提供している。 詳細A206650 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績3/6財務の健全性0/6配当金0/6報酬株価収益率（ 14 x）は、 Biotechs業界平均（ 28.4 x）を下回っています。今年は黒字化を達成 リスク分析最新の財務報告は1年以上前のものである すべてのリスクチェックを見るA206650 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩9.46k63.2% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-60b96b2016201920222025202620282031Revenue ₩96.0bEarnings ₩24.9bAdvancedSet Fair ValueView all narrativesEuBiologics Co., Ltd. 競合他社Medy-ToxSymbol: KOSDAQ:A086900Market cap: ₩557.2bNIBECSymbol: KOSDAQ:A138610Market cap: ₩218.5bNKMAXSymbol: KOSDAQ:A182400Market cap: ₩172.7bOnconic TherapeuticsSymbol: KOSDAQ:A476060Market cap: ₩713.4b価格と性能株価の高値、安値、推移の概要EuBiologics過去の株価現在の株価₩9,460.0052週高値₩17,700.0052週安値₩8,830.00ベータ0.181ヶ月の変化-20.17%3ヶ月変化-35.60%1年変化-24.14%3年間の変化25.97%5年間の変化-75.14%IPOからの変化86.59%最新ニュースお知らせ • Mar 27EuBiologics Co., Ltd. (KOSDAQ:A206650) announces an Equity Buyback for KRW 6,000 million worth of its shares.EuBiologics Co., Ltd. (KOSDAQ:A206650) announces a share repurchase program. Under the program, the company will repurchase up to KRW 6,000 million worth of its common stock pursuant to an agreement with NH Investment & Securities. The purpose of the program is stabilization of stock price and enhancement of shareholder value. The program will expire on September 30, 2026. As of March 25, 2026, the company had 0 shares available for acquisition within the dividend-eligible range and 0 shares from other stocks.お知らせ • Mar 07EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2026EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 125, wonmudong-gil, gangwon-do, chuncheon South KoreaValuation Update With 7 Day Price Move • Feb 24Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩16,200, the stock trades at a trailing P/E ratio of 23.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 98% over the past three years.New Risk • Feb 04New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩13,820, the stock trades at a trailing P/E ratio of 20.4x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 58% over the past three years.Valuation Update With 7 Day Price Move • Nov 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩13,990, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 16x in the Biotechs industry in South Korea. Total returns to shareholders of 22% over the past three years.最新情報をもっと見るRecent updatesお知らせ • Mar 27EuBiologics Co., Ltd. (KOSDAQ:A206650) announces an Equity Buyback for KRW 6,000 million worth of its shares.EuBiologics Co., Ltd. (KOSDAQ:A206650) announces a share repurchase program. Under the program, the company will repurchase up to KRW 6,000 million worth of its common stock pursuant to an agreement with NH Investment & Securities. The purpose of the program is stabilization of stock price and enhancement of shareholder value. The program will expire on September 30, 2026. As of March 25, 2026, the company had 0 shares available for acquisition within the dividend-eligible range and 0 shares from other stocks.お知らせ • Mar 07EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2026EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 125, wonmudong-gil, gangwon-do, chuncheon South KoreaValuation Update With 7 Day Price Move • Feb 24Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩16,200, the stock trades at a trailing P/E ratio of 23.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 98% over the past three years.New Risk • Feb 04New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩13,820, the stock trades at a trailing P/E ratio of 20.4x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 58% over the past three years.Valuation Update With 7 Day Price Move • Nov 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩13,990, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 16x in the Biotechs industry in South Korea. Total returns to shareholders of 22% over the past three years.New Risk • Mar 20New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.お知らせ • Mar 08EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2025EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 125, wonmudong-gil, dongsan-myeon, gangwon-do, chuncheon South KoreaNew Risk • Oct 05New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company.分析記事 • Aug 12Investors Holding Back On EuBiologics Co., Ltd. (KOSDAQ:206650)With a price-to-sales (or "P/S") ratio of 6.1x EuBiologics Co., Ltd. ( KOSDAQ:206650 ) may be sending bullish signals...分析記事 • May 30Is EuBiologics (KOSDAQ:206650) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Aug 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩20b free cash flow). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).お知らせ • Jul 15Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 TrialPOP Biotechnologies announced top line interim results of a Phase 3 clinical trial of EuCorVac-19, a COVID-19 vaccine candidate being developed by South Korean partner EuBiologics. EuCorVac-19 is a protein-based vaccine consisting of a vaccine antigen displayed on immunogenic nanoparticles, using POP BIO's Spontaneous-nanoliposome antigen particle (SNAP) technology. The phase 3 trial of EuCorVAC-19 was conducted in the Philippines in approximately 2,600 adults (NCT05572879). EuCorVac-18 demonstrated superior antibody immunogenicity compared to a World Health Organization Emergency Use Authorized adenoviral vector vaccine, thereby meeting the primary endpoint of the phase 3 trial. The formation of neutralizing antibodies, which prevent COVID-19 infection, was more than twice as high in EuCorVac- 19 compared to the control vaccine. EuCorVac-20 exhibited a high serological response rate with neutralizing antibody titers increasing after vaccination. In particular, the neutralizing antibody titers and serum response rates in subjects aged over 65 exceeded those of the control vaccine. EuCorVac-19's safety profile was further established in this phase 3 study. EuCorVac-19 showed a slightly lower incidence than the control vaccine of solicited adverse events and there was no difference between EuCorVac-19 and the control vaccine in the incidence of unsolicited adverse events. These results further validate the strength and synergy of POP BIO's SNAP and EuBiologics' EuIMT platform technologies used in the EuCorVac-19 vaccine. Further development of booster vaccines, new strain vaccines, and combination vaccines for COVID-19 will be significantly more straightforward in the future. EuCorVac-19 was already shown to be safe and immunogenic in a Phase I/II clinical trial, the results of which were announced in December 2021. The Philippine Phase 3 trial, conducted since third quarter of 2022, were supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the ministry of Health & Welfare, Republic of Korea. Based on the results of this clinical study, EuBiologics plans to apply for product approval in the Philippines shortly. Later this year, results will become available from a second independent Phase 3 clinical study being carried out in the Democratic Republic of Congo.お知らせ • Feb 04Eubiologics Co., Ltd. Announces Phase Iii Clinical Trial Ind Approval of Eucorvac-19, Covid-19 Vaccine Candidate, in South KoreaEuBiologics Co., Ltd. announced on Jan. 28 that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, obtained approval to conduct Phase III comparison clinical trials from the Ministry of Food and Drug Safety in South Korea. Eubiologics is able to commence Phase III comparison trial for 4,000 healthy participants including the Philippines, Bangladesh and other countries based on the standard comparison clinical trial guideline by the Ministry of Food and Drug Safety in Korea. Eubiologics will work closely with the global CROs for recruiting the participants to expedite the entire process in low vaccination rate countries and will also expedite the trial result analysis to advance EuCorVac-19’s regulatory approval and commercialization. Eubiologics is developing EuCorVac-19, its vaccine platform, which consists of owned antigen, EulMT in-licensed from Korea Institute of Science and Technology and SNAP technology of POP Biotechnologies that EuBiologics has invested. The company has announced Phase I/II trial interim results in December 2021. On the other hand, as EuCorVac-19 has already proved its safety and efficacy through Phase I/II clinical trial, the company expects to expedite the development of Omicron variant vaccine based on the same platform used for EuCorVac-19. Currently, the pre-clinical trial of Mouse immunogenicity test and TG mouse which is transformed from human gene are under progress and the company plans to proceed with the human trial within the 1st half of 2022. In addition, a booster vaccine is necessary due to the dominance of the Omicron variant, and thus the company will commence its trial to prove efficacy as a booster vaccine. Eubiologics has 2 main animal-based bioreactors to produce recombinant protein antigens at Chuncheon Plant 1 and EcML which is adjuvant at Chuncheon Plant 2. The total capacity of COVID-19 vaccine is from 100M to 200M doses per year. EuCorVac-19 vaccine uses the same type of cell line which is for antibody treatment, so if the company uses these facilities, its manufacturing capacity can be further expanded. Eubiologics has already received funds for Phase I/II March 2021 from the new drug development committee of the Ministry of Health and Welfare in Korea and recently submitted the application for phase III trial to get additional financial assistance.Is New 90 Day High Low • Feb 18New 90-day low: ₩17,300The company is down 1.0% from its price of ₩17,450 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 2.0% over the same period.お知らせ • Feb 10EuBiologics Co., Ltd., Annual General Meeting, Mar 25, 2021EuBiologics Co., Ltd., Annual General Meeting, Mar 25, 2021, at 10:00 Korea Standard Time.お知らせ • Jan 22EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in KoreaEuBiologics announced on January 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial. The Phase I trial is designed for 50 healthy adults aged from 19 to 50 years old and will be conducted at ‘the Catholic University of Korea Eunpyeong St. Mary’s Hospital’ evaluating safety, tolerance and immunogenicity. The Phase II trial will be subsequently carried out for 230 adults aged from 19 to 75 years old in four hospitals located in Seoul metropolitan area in order to evaluate dosage and vaccine immunogenicity. EuCorVac-19 under development by EuBiologics is a safe vaccine formulated with the coronavirus spike protein using the recombinant protein technology and with a potent adjuvant, similar to the other virus vaccines already licensed in the world. EuCorVac-19 is a liquid injection in glass vials and can be stored and distributed at refrigerated temperatures which can take advantage of the general distribution system for biopharmaceuticals. EuBiologics plans to consult with the Korean Ministry of Food and Drug Safety in order to progress the Phase III clinical trial later this year based on the interim results of the Phase I/II trial available no later than June 2021 and receive an emergency use approval of EuCorVac-19, as early as possible. EuBiologics also has a GMP accredited facility which can manufacture recombinant protein antigens and adjuvants, with confidence to provide competitive pricing.Is New 90 Day High Low • Jan 04New 90-day high: ₩22,350The company is up 3.0% from its price of ₩21,800 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 18% over the same period.分析記事 • Dec 08Does EuBiologics (KOSDAQ:206650) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Nov 12New 90-day low: ₩16,000The company is down 9.0% from its price of ₩17,500 on 14 August 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 5.0% over the same period.Is New 90 Day High Low • Oct 26New 90-day low: ₩16,300The company is down 7.0% from its price of ₩17,450 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 12% over the same period.株主還元A206650KR BiotechsKR 市場7D-3.6%-1.9%-0.3%1Y-24.1%10.9%165.0%株主還元を見る業界別リターン: A206650過去 1 年間で10.9 % の収益を上げたKR Biotechs業界を下回りました。リターン対市場: A206650は、過去 1 年間で165 % のリターンを上げたKR市場を下回りました。価格変動Is A206650's price volatile compared to industry and market?A206650 volatilityA206650 Average Weekly Movement5.5%Biotechs Industry Average Movement10.7%Market Average Movement8.7%10% most volatile stocks in KR Market16.1%10% least volatile stocks in KR Market4.4%安定した株価: A206650 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A206650の 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2010n/aYeong-Ok Baikeubiologics.comバイオ医薬品会社であるEuBiologics Co.経口コレラ予防ワクチンEuvichol Plus、ジフテリアトキソイドワクチンrCRM197を提供している。また、細胞膜用ワクチンEcMLやCOVID-19診断キットも提供している。さらに、医薬品製造、細胞バンク製造、原薬製造からなるCMOサービスも提供している。さらに、細胞株開発、GMP製造、バリデーション、薬事サポートを含むCRMOサービスを提供し、タンパク質ベースの治療薬や抗体を製造する施設を運営している。さらに、ロットリリース、安定性、原材料、方法バリデーション試験サービスを含む受託試験サービスも提供している。ユビオロジックス社は2010年に設立され、韓国ソウルに本社を置いている。もっと見るEuBiologics Co., Ltd. 基礎のまとめEuBiologics の収益と売上を時価総額と比較するとどうか。A206650 基礎統計学時価総額₩347.40b収益（TTM）₩24.87b売上高(TTM)₩96.04b14.0xPER（株価収益率3.6xP/SレシオA206650 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A206650 損益計算書（TTM）収益₩96.04b売上原価₩0売上総利益₩96.04bその他の費用₩71.17b収益₩24.87b直近の収益報告Dec 31, 2024次回決算日該当なし一株当たり利益（EPS）677.12グロス・マージン100.00%純利益率25.89%有利子負債／自己資本比率0.0%A206650 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/13 20:40終値2026/06/12 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋EuBiologics Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Hyun Dong SungKB Securities Co., Ltd.Wan KuNH Investment & Securities Co., Ltd.
お知らせ • Mar 27EuBiologics Co., Ltd. (KOSDAQ:A206650) announces an Equity Buyback for KRW 6,000 million worth of its shares.EuBiologics Co., Ltd. (KOSDAQ:A206650) announces a share repurchase program. Under the program, the company will repurchase up to KRW 6,000 million worth of its common stock pursuant to an agreement with NH Investment & Securities. The purpose of the program is stabilization of stock price and enhancement of shareholder value. The program will expire on September 30, 2026. As of March 25, 2026, the company had 0 shares available for acquisition within the dividend-eligible range and 0 shares from other stocks.
お知らせ • Mar 07EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2026EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 125, wonmudong-gil, gangwon-do, chuncheon South Korea
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩16,200, the stock trades at a trailing P/E ratio of 23.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 98% over the past three years.
New Risk • Feb 04New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩13,820, the stock trades at a trailing P/E ratio of 20.4x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 58% over the past three years.
Valuation Update With 7 Day Price Move • Nov 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩13,990, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 16x in the Biotechs industry in South Korea. Total returns to shareholders of 22% over the past three years.
お知らせ • Mar 27EuBiologics Co., Ltd. (KOSDAQ:A206650) announces an Equity Buyback for KRW 6,000 million worth of its shares.EuBiologics Co., Ltd. (KOSDAQ:A206650) announces a share repurchase program. Under the program, the company will repurchase up to KRW 6,000 million worth of its common stock pursuant to an agreement with NH Investment & Securities. The purpose of the program is stabilization of stock price and enhancement of shareholder value. The program will expire on September 30, 2026. As of March 25, 2026, the company had 0 shares available for acquisition within the dividend-eligible range and 0 shares from other stocks.
お知らせ • Mar 07EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2026EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 125, wonmudong-gil, gangwon-do, chuncheon South Korea
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩16,200, the stock trades at a trailing P/E ratio of 23.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 98% over the past three years.
New Risk • Feb 04New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩13,820, the stock trades at a trailing P/E ratio of 20.4x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 58% over the past three years.
Valuation Update With 7 Day Price Move • Nov 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩13,990, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 16x in the Biotechs industry in South Korea. Total returns to shareholders of 22% over the past three years.
New Risk • Mar 20New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.
お知らせ • Mar 08EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2025EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 125, wonmudong-gil, dongsan-myeon, gangwon-do, chuncheon South Korea
New Risk • Oct 05New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company.
分析記事 • Aug 12Investors Holding Back On EuBiologics Co., Ltd. (KOSDAQ:206650)With a price-to-sales (or "P/S") ratio of 6.1x EuBiologics Co., Ltd. ( KOSDAQ:206650 ) may be sending bullish signals...
分析記事 • May 30Is EuBiologics (KOSDAQ:206650) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Aug 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩20b free cash flow). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).
お知らせ • Jul 15Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 TrialPOP Biotechnologies announced top line interim results of a Phase 3 clinical trial of EuCorVac-19, a COVID-19 vaccine candidate being developed by South Korean partner EuBiologics. EuCorVac-19 is a protein-based vaccine consisting of a vaccine antigen displayed on immunogenic nanoparticles, using POP BIO's Spontaneous-nanoliposome antigen particle (SNAP) technology. The phase 3 trial of EuCorVAC-19 was conducted in the Philippines in approximately 2,600 adults (NCT05572879). EuCorVac-18 demonstrated superior antibody immunogenicity compared to a World Health Organization Emergency Use Authorized adenoviral vector vaccine, thereby meeting the primary endpoint of the phase 3 trial. The formation of neutralizing antibodies, which prevent COVID-19 infection, was more than twice as high in EuCorVac- 19 compared to the control vaccine. EuCorVac-20 exhibited a high serological response rate with neutralizing antibody titers increasing after vaccination. In particular, the neutralizing antibody titers and serum response rates in subjects aged over 65 exceeded those of the control vaccine. EuCorVac-19's safety profile was further established in this phase 3 study. EuCorVac-19 showed a slightly lower incidence than the control vaccine of solicited adverse events and there was no difference between EuCorVac-19 and the control vaccine in the incidence of unsolicited adverse events. These results further validate the strength and synergy of POP BIO's SNAP and EuBiologics' EuIMT platform technologies used in the EuCorVac-19 vaccine. Further development of booster vaccines, new strain vaccines, and combination vaccines for COVID-19 will be significantly more straightforward in the future. EuCorVac-19 was already shown to be safe and immunogenic in a Phase I/II clinical trial, the results of which were announced in December 2021. The Philippine Phase 3 trial, conducted since third quarter of 2022, were supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the ministry of Health & Welfare, Republic of Korea. Based on the results of this clinical study, EuBiologics plans to apply for product approval in the Philippines shortly. Later this year, results will become available from a second independent Phase 3 clinical study being carried out in the Democratic Republic of Congo.
お知らせ • Feb 04Eubiologics Co., Ltd. Announces Phase Iii Clinical Trial Ind Approval of Eucorvac-19, Covid-19 Vaccine Candidate, in South KoreaEuBiologics Co., Ltd. announced on Jan. 28 that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, obtained approval to conduct Phase III comparison clinical trials from the Ministry of Food and Drug Safety in South Korea. Eubiologics is able to commence Phase III comparison trial for 4,000 healthy participants including the Philippines, Bangladesh and other countries based on the standard comparison clinical trial guideline by the Ministry of Food and Drug Safety in Korea. Eubiologics will work closely with the global CROs for recruiting the participants to expedite the entire process in low vaccination rate countries and will also expedite the trial result analysis to advance EuCorVac-19’s regulatory approval and commercialization. Eubiologics is developing EuCorVac-19, its vaccine platform, which consists of owned antigen, EulMT in-licensed from Korea Institute of Science and Technology and SNAP technology of POP Biotechnologies that EuBiologics has invested. The company has announced Phase I/II trial interim results in December 2021. On the other hand, as EuCorVac-19 has already proved its safety and efficacy through Phase I/II clinical trial, the company expects to expedite the development of Omicron variant vaccine based on the same platform used for EuCorVac-19. Currently, the pre-clinical trial of Mouse immunogenicity test and TG mouse which is transformed from human gene are under progress and the company plans to proceed with the human trial within the 1st half of 2022. In addition, a booster vaccine is necessary due to the dominance of the Omicron variant, and thus the company will commence its trial to prove efficacy as a booster vaccine. Eubiologics has 2 main animal-based bioreactors to produce recombinant protein antigens at Chuncheon Plant 1 and EcML which is adjuvant at Chuncheon Plant 2. The total capacity of COVID-19 vaccine is from 100M to 200M doses per year. EuCorVac-19 vaccine uses the same type of cell line which is for antibody treatment, so if the company uses these facilities, its manufacturing capacity can be further expanded. Eubiologics has already received funds for Phase I/II March 2021 from the new drug development committee of the Ministry of Health and Welfare in Korea and recently submitted the application for phase III trial to get additional financial assistance.
Is New 90 Day High Low • Feb 18New 90-day low: ₩17,300The company is down 1.0% from its price of ₩17,450 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 2.0% over the same period.
お知らせ • Feb 10EuBiologics Co., Ltd., Annual General Meeting, Mar 25, 2021EuBiologics Co., Ltd., Annual General Meeting, Mar 25, 2021, at 10:00 Korea Standard Time.
お知らせ • Jan 22EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in KoreaEuBiologics announced on January 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial. The Phase I trial is designed for 50 healthy adults aged from 19 to 50 years old and will be conducted at ‘the Catholic University of Korea Eunpyeong St. Mary’s Hospital’ evaluating safety, tolerance and immunogenicity. The Phase II trial will be subsequently carried out for 230 adults aged from 19 to 75 years old in four hospitals located in Seoul metropolitan area in order to evaluate dosage and vaccine immunogenicity. EuCorVac-19 under development by EuBiologics is a safe vaccine formulated with the coronavirus spike protein using the recombinant protein technology and with a potent adjuvant, similar to the other virus vaccines already licensed in the world. EuCorVac-19 is a liquid injection in glass vials and can be stored and distributed at refrigerated temperatures which can take advantage of the general distribution system for biopharmaceuticals. EuBiologics plans to consult with the Korean Ministry of Food and Drug Safety in order to progress the Phase III clinical trial later this year based on the interim results of the Phase I/II trial available no later than June 2021 and receive an emergency use approval of EuCorVac-19, as early as possible. EuBiologics also has a GMP accredited facility which can manufacture recombinant protein antigens and adjuvants, with confidence to provide competitive pricing.
Is New 90 Day High Low • Jan 04New 90-day high: ₩22,350The company is up 3.0% from its price of ₩21,800 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 18% over the same period.
分析記事 • Dec 08Does EuBiologics (KOSDAQ:206650) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Nov 12New 90-day low: ₩16,000The company is down 9.0% from its price of ₩17,500 on 14 August 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 5.0% over the same period.
Is New 90 Day High Low • Oct 26New 90-day low: ₩16,300The company is down 7.0% from its price of ₩17,450 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 12% over the same period.
